The company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.

Sarepta Therapeutics has paused U.S. shipments of its gene therapy Elevidys after two teenagers with Duchenne muscular ...

Sarepta Therapeutics said on Monday it will pause all shipments of Elevidys in the United States after two teenage boys with a rare condition called Duchenne muscular dystrophy, who had received the ...

Sarepta Therapeutics will cut 500 jobs and add a serious warning on the label of its muscle-disorder gene therapy Elevidys, the drugmaker said on Wednesday, following the recent deaths of two patients ...

The company will pause several gene therapy development programs, for which it intends to seek partners and other strategic alternatives.

Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...

Sarepta Therapeutics said on Wednesday it would lay off 36% of its workforce, or about 500 employees, after two recent deaths of patients who had received its gene therapy, Elevidys. Shares of the ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.